Pacific Edge shows modest momentum with Q4 test volumes rising 2.7% as payer expansion accelerates. The ASX-listed biotech company expanded commercial coverage significantly, securing new policies from BCBS North Carolina and South Carolina covering 4.2 million lives combined, plus Highmark coverage of 7 million lives for its Cxbladder Monitor product. US volumes grew 1.0% to 4,064 tests while Asia Pacific surged 7.7% to 1,518 tests. Despite operational headwinds from winter storms and a reduced sales force, efficiency metrics improved substantially with tests per sales FTE rising to 530 from 335. The company expects a draft Medicare local coverage determination by late Q2 FY27, potentially as early as September 2026, following strong expert support demonstrated at the February Novitas Contractor Advisory Committee meeting.
Post from MarketNews_en
Log in to interact with content.